Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Is there a role for radiation to the primary mediastinal disease in metastatic thymic neuroendocrine carcinoma with the primary as the only residual disease after systemic therapy?
What dose would you use to treat?
Related Questions
Do you use an LAD constraint in the setting of BID thoracic radiation for SCLC?
How do you assess whether a patient will be a good DIBH candidate for lung or abdomen treatments?
Can palliative radiation be used to treat recurrent malignant pleural effusion in NSCLC?
Would you offer empiric lung SBRT for two growing FDG-avid lung lesions in a patient with severe COPD on oxygen?
Is there evidence supporting the role of SBRT in the management of oligometastatic stage IV NSCLC?
In a patient who underwent cryoablation for early NSCLC, is there a role for giving preemptive further local therapy?
In resected N2 NSCLC, what nodal pathologic characteristics prompt you to recommend PORT?
Do more fractionated regimens reduce severe toxicity over SBRT in patients with ILD and early-stage NSCLC?
What is the recommendation for persistent PET uptake and elevated catecholamines at 4 months following subtotal resection and adjuvant radiation for a thoracic secretory paraganglioma?
Would you offer SBRT for primary pulmonary adenoid cystic carcinoma in a patient who was medically not a surgical candidate?